HRP20191653T1 - N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava - Google Patents
N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava Download PDFInfo
- Publication number
- HRP20191653T1 HRP20191653T1 HRP20191653TT HRP20191653T HRP20191653T1 HR P20191653 T1 HRP20191653 T1 HR P20191653T1 HR P20191653T T HRP20191653T T HR P20191653TT HR P20191653 T HRP20191653 T HR P20191653T HR P20191653 T1 HRP20191653 T1 HR P20191653T1
- Authority
- HR
- Croatia
- Prior art keywords
- degrees
- polymorph
- theta
- use according
- diffraction pattern
- Prior art date
Links
- 210000005096 hematological system Anatomy 0.000 title claims 4
- 230000002062 proliferating effect Effects 0.000 title claims 4
- 239000004305 biphenyl Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- UQRICAQPWZSJNF-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;hydrobromide Chemical compound Br.C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 UQRICAQPWZSJNF-UHFFFAOYSA-N 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000001757 thermogravimetry curve Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000035865 Chronic mast cell leukemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000002797 childhood leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000009612 pediatric lymphoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (23)
1. N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2H-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnog poremećaja stanica hematološkog sustava.
2. Spoj za uporabu prema patentnom zahtjevu 1, koji je monohidrobromid.
3. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time što je navedeni spoj kristalan.
4. Spoj za uporabu prema bilo kojem od prethodno navedenih patentnih zahtjeva, naznačen time što je navedeni spoj bez nečistoća.
5. Spoj za uporabu prema bilo kojem od prethodno navedenih patentnih zahtjeva, naznačen time što je navedeni spoj kristalna kruta tvar koja je suštinski bez amorfnog N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’-bifenil]-3-karboksamid hidrobromida.
6. Polimorf A N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2H-piran-4-il)amino)-4-metil-4’-(morfolinometil)-[1,1’-bifenil]-3-karboksamid hidrobromida za uporabu u liječenju proliferativnog poremećaja stanica hematološkog sustava; naznačen time što polimorf A prikazuje rendgenski difraktogram praha koji ima jedan ili više karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja i 22.0 +/- 0.3 stupnja 2-teta.
7. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima karakteristične vrhove izražene u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja i 22.0 +/- 0.3 stupnja 2-teta.
8. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima jedan ili više karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja, i oko 23.6 +/- 0.3 stupnja 2-teta.
9. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 5 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
10. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 6 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
11. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 7 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
12. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 8 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
13. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 9 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
14. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima najmanje 10 karakterističnih vrhova izraženih u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
15. Polimorf za uporabu prema patentnom zahtjevu 7; naznačen time što polimorf prikazuje rendgenski difraktogram praha koji ima karakteristične vrhove izražene u stupnjevima 2-teta na 3.9 +/- 0.3 stupnja, 10.1 +/- 0.3 stupnja, 14.3 +/- 0.3 stupnja, 17.5 +/- 0.3 stupnja, 18.7 +/- 0.3 stupnja, 20.6 +/- 0.3 stupnja, 20.9 +/- 0.3 stupnja, 21.8 +/- 0.3 stupnja, 22.0 +/- 0.3 stupnja, 23.3 +/- 0.3 stupnja i 23.6 +/- 0.3 stupnja 2-teta.
16. Polimorf za uporabu prema bilo kojem od patentnih zahtjeva 6 do 15, naznačen time što polimorf prikazuje rendgenski difraktogram praha koji je suštinski u skladu sa slikom 1 i/ili polimorf prikazuje rendgenski difraktogram praha koji je suštinski u skladu s tablicom 1:
Tablica 1
17. Polimorf za uporabu prema bilo kojem od patentnih zahtjeva 6 do 16, naznačen time što polimorf prikazuje termogram diferencijalne skenirajuće kalorimetrije koji ima karakterističan vrh izražen u jedinicama °C, na temperaturi od 255 +/- 5°C.
18. Polimorf za uporabu prema bilo kojem od patentnih zahtjeva 6 do 17, naznačen time što polimorf prikazuje termogram diferencijalne skenirajuće kalorimetrije koji je suštinski u skladu sa slikom 3.
19. Polimorf za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je proliferativni poremećaj stanica hematološkog sustava hematološki karcinom.
20. Polimorf za uporabu prema patentnom zahtjevu 19, naznačen time što je hematološki karcinom odabran od multiplog mijeloma, limfoma, leukemije, mijeloidnih neoplazmi i neoplazmi mastocita.
21. Polimorf za uporabu prema patentnom zahtjevu 20, naznačen time što je limfom odabran od Hodgkinovog limfoma, limfoma dječjeg uzrasta i limfoma limfocitnog i kožnog porijekla.
22. Polimorf za uporabu prema patentnom zahtjevu 20, naznačen time što je leukemija odabrana od leukemije dečjeg uzrasta, leukemije vlasastih stanica, akutne limfocitne leukemije, akutne mijelocitne leukemije, kronične limfocitne leukemije, kronične mijelocitne leukemije, kronične mijeloične leukemije i leukemije mastocita.
23. Polimorf za uporabu prema patentnom zahtjevu 20, naznačen time što je hematološki karcinom multipli mijelom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624215P | 2012-04-13 | 2012-04-13 | |
| EP16191716.6A EP3184523B1 (en) | 2012-04-13 | 2013-04-11 | N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[l,1'-biphenyl]-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191653T1 true HRP20191653T1 (hr) | 2020-02-21 |
Family
ID=49328166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170295TT HRP20170295T1 (hr) | 2012-04-13 | 2017-02-22 | Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 |
| HRP20191653TT HRP20191653T1 (hr) | 2012-04-13 | 2019-09-13 | N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170295TT HRP20170295T1 (hr) | 2012-04-13 | 2017-02-22 | Oblik soli inhibitora ljudske histonske metiltransferaze ezh2 |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9394283B2 (hr) |
| EP (4) | EP2836491B1 (hr) |
| JP (3) | JP6255382B2 (hr) |
| KR (3) | KR102120883B1 (hr) |
| CN (2) | CN104603130B (hr) |
| AU (2) | AU2013245878B2 (hr) |
| BR (1) | BR112014025508B1 (hr) |
| CA (1) | CA2870005C (hr) |
| CY (2) | CY1119383T1 (hr) |
| DK (3) | DK3628670T3 (hr) |
| ES (3) | ES2745016T3 (hr) |
| HR (2) | HRP20170295T1 (hr) |
| HU (3) | HUE060881T2 (hr) |
| IL (4) | IL296199A (hr) |
| IN (1) | IN2014DN09068A (hr) |
| LT (2) | LT2836491T (hr) |
| MX (1) | MX362339B (hr) |
| NZ (1) | NZ700761A (hr) |
| PL (3) | PL2836491T3 (hr) |
| PT (3) | PT2836491T (hr) |
| RS (2) | RS59392B1 (hr) |
| RU (1) | RU2658911C2 (hr) |
| SG (3) | SG10201608577RA (hr) |
| SI (2) | SI2836491T1 (hr) |
| WO (1) | WO2013155317A1 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| RU2019126908A (ru) | 2012-04-13 | 2020-01-13 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| HUE060881T2 (hu) | 2012-04-13 | 2023-04-28 | Epizyme Inc | Sóforma az EZH2 gátláshoz |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2887243C (en) * | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| EP2906537B1 (en) | 2012-10-15 | 2020-03-11 | Epizyme, Inc. | Substituted benzene compounds |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20160003115A (ko) | 2013-04-30 | 2016-01-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| JP2016523955A (ja) | 2013-07-10 | 2016-08-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｚｅｓｔｅホモログ２エンハンサー阻害剤 |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
| AU2014337121A1 (en) * | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| WO2015077193A1 (en) * | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| KR102473113B1 (ko) | 2013-12-06 | 2022-12-01 | 에피자임, 인코포레이티드 | 암 치료를 위한 병용 요법 |
| SG10201811128RA (en) | 2014-06-17 | 2019-01-30 | Epizyme Inc | Ezh2 inhibitors for treating lymphoma |
| EP3157928B1 (en) | 2014-06-20 | 2019-02-13 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
| NZ730365A (en) | 2014-10-16 | 2024-03-22 | Epizyme Inc | Method for treating cancer |
| MX2017006089A (es) * | 2014-11-17 | 2017-12-11 | Epizyme Inc | Metodo para tratar el cancer. |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| AU2016252546A1 (en) | 2015-04-20 | 2017-11-02 | Epizyme, Inc. | Combination therapy for treating cancer |
| US20180311251A1 (en) | 2015-06-10 | 2018-11-01 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| JP2019503391A (ja) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| AU2017273726B2 (en) * | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
| US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
| US11214561B2 (en) * | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110944628A (zh) | 2017-06-02 | 2020-03-31 | Epizyme股份有限公司 | 使用ezh2抑制剂治疗癌症 |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| EP4017527A1 (en) | 2019-08-22 | 2022-06-29 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| IL294108A (en) * | 2019-12-20 | 2022-08-01 | Epizyme Inc | Crystalline salt of hydrobromide of ezh2 inhibitor, its preparation and effective pharmaceutical composition for cancer treatment |
| WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| JP2002525352A (ja) | 1998-09-30 | 2002-08-13 | ザ、プロクター、エンド、ギャンブル、カンパニー | ２−置換ケトアミド |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| KR100828982B1 (ko) | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체 |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| WO2003070277A1 (fr) | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| WO2005095386A1 (en) | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| WO2005118796A2 (en) | 2004-06-01 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| WO2006130720A2 (en) | 2005-06-02 | 2006-12-07 | University Of North Carolina At Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| PT1940821E (pt) | 2005-10-19 | 2013-05-29 | Gruenenthal Gmbh | Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos |
| KR20080057296A (ko) | 2005-10-21 | 2008-06-24 | 머크 앤드 캄파니 인코포레이티드 | 칼륨 채널 억제제 |
| EP1941060B1 (en) | 2005-10-28 | 2012-02-29 | The University of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| MX2008014616A (es) | 2006-05-15 | 2008-11-28 | Irm Llc | Compuestos y composiciones de tereftalamato, y su uso como inhibidores de integrasa de vih. |
| CA2652634A1 (en) | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certain substituted quinolones, compositions, and uses thereof |
| US8022246B2 (en) | 2006-10-10 | 2011-09-20 | The Burnham Institute For Medical Research | Neuroprotective compositions and methods |
| JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
| EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US8299093B2 (en) | 2008-08-08 | 2012-10-30 | New York Blood Center, Inc. | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| EP2521558A4 (en) | 2009-12-30 | 2013-07-03 | Avon Prod Inc | TOPICAL LIGHTING COMPOSITION AND USES THEREOF |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| SI2566327T1 (sl) * | 2010-05-07 | 2017-07-31 | Glaxosmithkline Llc | Indoli |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| JP6389036B2 (ja) | 2010-09-10 | 2018-09-12 | エピザイム インコーポレイテッド | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| AU2013232229B2 (en) | 2012-03-12 | 2017-11-23 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| HUE060881T2 (hu) * | 2012-04-13 | 2023-04-28 | Epizyme Inc | Sóforma az EZH2 gátláshoz |
| RU2019126908A (ru) | 2012-04-13 | 2020-01-13 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
| PL3057962T3 (pl) | 2013-10-16 | 2024-01-29 | Epizyme, Inc. | Postać soli chlorowodorku do inhibicji ezh2 |
-
2013
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/hu unknown
- 2013-04-11 MX MX2014012380A patent/MX362339B/es active IP Right Grant
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/ja active Active
- 2013-04-11 RS RSP20191175 patent/RS59392B1/sr unknown
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 PT PT137749792T patent/PT2836491T/pt unknown
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/da active
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/ko active IP Right Grant
- 2013-04-11 PL PL13774979T patent/PL2836491T3/pl unknown
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/lt unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/sl unknown
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 SI SI201331566T patent/SI3184523T1/sl unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/pl unknown
- 2013-04-11 IL IL296199A patent/IL296199A/en unknown
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/ru not_active Application Discontinuation
- 2013-04-11 ES ES16191716T patent/ES2745016T3/es active Active
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/zh active Active
- 2013-04-11 KR KR1020227029511A patent/KR20220123339A/ko not_active Application Discontinuation
- 2013-04-11 PL PL16191716T patent/PL3184523T3/pl unknown
- 2013-04-11 PT PT16191716T patent/PT3184523T/pt unknown
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/zh active Active
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/hu unknown
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/pt active IP Right Grant
- 2013-04-11 RS RS20170198A patent/RS55690B1/sr unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 PT PT191804798T patent/PT3628670T/pt unknown
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/da active
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/ko active IP Right Grant
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/es active Active
- 2013-04-11 ES ES19180479T patent/ES2931316T3/es active Active
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/lt unknown
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-02-22 HR HRP20170295TT patent/HRP20170295T1/hr unknown
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/el unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/ja active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/ja active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/hr unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/el unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US20230140327A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191653T1 (hr) | N-((4,6-dimetil-2-okso-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il)amino)-4-metil-4' (morfolinometil)-[l,1'-bifenil]-3-karboksamid hidrobromid za uporabu u liječenju proliferativnih poremećaja stanica hematološkog sustava | |
| PE20140002A1 (es) | Proceso de elaboracion para derivados de pirimidina | |
| CR20150541A (es) | Compuestos y composiciones nuevos para la inhibición de fasn | |
| PE20161273A1 (es) | Forma salina de hidrocloruro para la inhibicion de ezh2 | |
| CR20130104A (es) | Compuestos y composiciones novedosos para la inhibicion de nampt | |
| CU24424B1 (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| WO2011100726A3 (en) | Architectural construct having for example a plurality of architectural crystals | |
| TN2015000516A1 (en) | Chemical compounds | |
| BR112014030743A2 (pt) | inibidores de neprilisina | |
| PE20160840A1 (es) | Formas cristalinas de compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) | |
| EA201791873A1 (ru) | Полиморф ингибиторов syk | |
| CR20140510A (es) | Nucleósidos de espirooxetano de uracilo | |
| CU24387B1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| MX2013012760A (es) | Nuevos compuestos y composiciones para la inhibicion de nampt. | |
| IN2014CN03238A (hr) | ||
| UA112626C2 (uk) | Стабільна кристалічна форма типірацилу гідрохлориду і спосіб її кристалізації | |
| EP2929886A4 (en) | COMPOSITION WITH PHOSPHODIESTERASE TYPE-5 INHIBITOR TO INHIBIT APOPTOSIS OF NERVOUS CELLS | |
| BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
| IN2015DN03313A (hr) | ||
| HK1221714A1 (zh) | 具有至少三個碳原子的醇到烴混合原料的催化轉化 | |
| BR112014000181A2 (pt) | bloqueamento de anticorpo agr2 e uso dos mesmos | |
| BR112014004403A2 (pt) | compostos fotorreativos | |
| PE20140123A1 (es) | Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil)-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1 | |
| RS53001B (en) | DELTA CRYSTAL FORM OF ARGININE SALT PERINDOPRIL, PROCEDURE FOR ITS MANUFACTURE AND PHARMACEUTICAL MIXTURES CONTAINING IT | |
| FR2970000B1 (fr) | Nouveau procede de synthese de l'agomelatine |